Navigation Links
Results of the AIDA STEMI MRI sub-study presented at TCT 2012
Date:10/25/2012

MIAMI, FL OCTOBER 25, 2012 A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV). The results of the AIDA STEMI MRI sub-study were presented today the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The AIDA STEMI trial was a randomized, open-label, multicenter trial in 2,065 patients presenting with ST-elevation myocardial infarction (STEMI) comparing intracoronary (IC) versus intravenous (IV) abciximab during PCI with subsequent 12 hour intravenous infusion. Last year, researchers reported that the trial found that both methods yielded similar 90-day rates of all-cause mortality, recurrent heart attack or congestive heart failure.

Researchers enrolled 703 patients within the overall trial in a cardiac magnetic resonance imaging sub-study, one of the largest MRI sub-studies conducted in patients with STEMI. Cardiac MRI allows for a more sensitive investigation of the mechanistic and pathophysiological effects of STEMI therapies on myocardial damage and reperfusion injury.

Cardiac MRI was completed within four days after heart attack using a standardized protocol including edema imaging and late gadolinium enhancement. Researchers examined infarct size, myocardial salvage, microvascular obstruction and ventricular function to determine the potential benefits of intracoronary compared to intravenous application of abciximab.

The amount of myocardium at risk and final infarct size did not differ significantly between the IC versus the IV abciximab groups. Consequently, the myocardial salvage index was similar between the two groups. In further detailed analysis there were no differences in microvascular obstruction between both treatment groups.

"Results of this sub-study demonstrate that intracoronary as compared to intravenous abciximab did not result in a difference in myocardial damage or reperfusion injury," said lead investigator Holger Thiele, MD. Dr. Thiele is Co-Director of the University of Leipzig - Heart Center in Germany.

"These findings confirm similarities in the combined endpoint of death, reinfarction and congestive heart failure found between the two methods in the AIDA STEMI trial," Dr. Thiele said.

Dr. Thiele will present the AIDA STEMI MRI sub-study on Thursday October 25 at 12:30 PM EST in the Main Arena (Hall D) at the Miami Beach Convention Center.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PC trial presented at TCT 2012
2. Results of the POSEIDON trial presented at TCT 2012
3. 1-year results of ADAPT-DES presented at TCT 2012
4. Comparison of Obesity Surgeries Turns Up Surprising Results
5. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
6. Missed Diagnoses in ICU Often Have Deadly Results: Review
7. Anti-clotting drugs yield similar results
8. Late-Night Cramming May Hurt School Test Results
9. New survey: Women want to SEE breast reconstruction results before cancer surgery
10. Weight-loss surgery results in positive changes in social life, medical conditions
11. Many Test Results Left Unread as Patients Leave Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... LINCOLN, R.I. (PRWEB) , ... May 02, 2016 ... ... , an educational website to help consumers better understand life insurance throughout various ... helpful resources, including an easy-to-use life insurance needs calculator and content specific to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, ... with same day treatments. In the past, many necessary dental treatments could require multiple ... with multiple anesthetic shots and extra chair time. Not only could this be inconvenient, ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Further establishing ... to announce that the new WHIMZEES Variety Value Boxes were selected from over 1,000 ... Product Showcase Award. , WHIMZEES natural dental chews for dogs are a favorite ...
(Date:5/2/2016)... RICHEY, Fla. (PRWEB) , ... ... ... and medical researchers report that many commonly used prescription medications, including anxiolytics, ... (1). To mitigate these risks, Novus Medical Detox Center —a leading ...
(Date:5/2/2016)... ... May 02, 2016 , ... A research team, ... groundbreaking studies that determined that the adjustability and adaptability of pediatric support surfaces ... of pressure injuries, which are now referred to as “pressure injuries” by the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- Treato , the single largest ... that it has been named a Cool Vendor by ... Sciences, 2016, Stephen Davies , Michael ... life-science- oriented analytics, algorithms and smart machine technology in ... medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
Breaking Medicine Technology: